CURED INC.
ABOUT US
CURED Inc. is an emerging biopharmaceutical company born as a university start-up in Yokohama located near Tokyo. The company is focused on the development of novel immunological therapeutics in the areas of infectious and inflammatory diseases.
CURED's R&D pipeline consists of targeted molecules with novel pharmacologic mechanisms of action addressing multiple large market opportunities in areas of significant unmet medical need. All R&D pipeline candidates are in last-stage preclinical animal studies with clinical trial initiation planned in approximately two years.
CURED, through its proprietary network, has the ability to identify and secure pharmaceutical seeds invented in world-renowned research and medical institutions. The Company has the expertise to rapidly grow these seeds into clinical candidates and to license them to global pharmaceutical companies.
CURED's management team is made up of experienced executives with proven track records in immunological science, pharmaceutical development and venture-backed biopharmaceutical business.
MANAGEMENT TEAM
Masahiro MICHISHITA, M.D., Ph.D.
Chairman & Chief Executive Officer
Takushi NAKAJIMA
Chief Operating Officer
Chie SAKANAKA, M.D., Ph.D.
Clinical Development Unit
Mieko OTSU, Ph.D.
Quality Unit
Yui GOTO
General Affairs Unit
INVENTORS
Shuzo MATSUSHITA, M.D., Ph.D.
Professor, Clinical Retrovirology
Joint Research Center for Human Retrovirus Infection
Kumamoto University Campus
Chihaya IMAI, M.D., Ph.D.
Professor, Department of Pediatrics
Graduate School of Medicine and Pharmaceutical Sciences
University of Toyama
Seitaro TERAKURA, M.D., Ph.D.
Section Head, Cellular Immunotherapy Development
Senior Lecturer, Department of Hematology and Oncology
Nagoya University Graduate School of Medicine
MAJOR FINANCING
Higin Capital
Nissay Capital
Immuno-Biological Laboratories
Transgenic Group
RESEARCH AND DEVELOPMENT
--- PIPELINE ---
INFECTIOUS DISEASES
INFLAMMATORY DISEASES
--- PLATFORM TECHNOLOGIES FOR CELLULAR IMMUNOTHERAPY ---
PERSISTENCE ENHANCERS
OFF-THE-SHELF CELLS
INFECTIOUS DISEASES
An increasing body of evidence suggests that non-neutralizing Fc effector functions such as ADCC (antibody-dependent cellular cytotoxicity) have the curative potential for HIV chronic infections.
CURED's CRD-2101, a monoclonal antibody derived from a Japanese HIV controller, clearly shows much higher ADCC activity than other antibodies that are so-called broadly neutralizing antibodies being investigated in clinical trials. The Company successfully manufactures ADCC-enhanced CRD-2101 by utilizing a potelligent technology licensed from BioWa, a subsidiary of Kyowa Kirin.
The ADCC-enhanced CRD-2101 not only plays a direct role in eliminating latently infected HIV but also elicits multicellular immune responses ultimately resulting in long-lasting HIV control by adaptive immunity.
INFLAMMATORY DISEASES
CURED's CRD-3101 possesses potent pro-resolution properties.
The Company confirmed the efficacy of CRD-3101 in Alport syndrome, a chronic kidney disease caused by an inherited defect in type IV collagen, by utilizing a genetically engineered murine model. CRD-3101 potently and safely addresses multiple inflammatory indications including chronic kidney diseases. It has a strong safety profile that will allow CURED to enter clinical trials in the near future.
CURED seeks to form strategic alliances
with large pharmaceutical companies
established in particular disease areas.
